Cargando…

Health-Related Quality of Life of Patients Treated with Biological Agents and New Small-Molecule Drugs for Moderate to Severe Crohn’s Disease: A Systematic Review

Crohn’s disease (CD) leads to a poor health-related quality of life (HRQoL). This review aimed to investigate the effect of biological agents and small-molecule drugs in improving the HRQoL of patients with moderate to severe CD. We adopted a systematic protocol to search PubMed and Cochrane Central...

Descripción completa

Detalles Bibliográficos
Autores principales: Aladraj, Hasan, Abdulla, Mohamed, Guraya, Salman Yousuf, Guraya, Shaista Salman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267515/
https://www.ncbi.nlm.nih.gov/pubmed/35807044
http://dx.doi.org/10.3390/jcm11133743
_version_ 1784743737473105920
author Aladraj, Hasan
Abdulla, Mohamed
Guraya, Salman Yousuf
Guraya, Shaista Salman
author_facet Aladraj, Hasan
Abdulla, Mohamed
Guraya, Salman Yousuf
Guraya, Shaista Salman
author_sort Aladraj, Hasan
collection PubMed
description Crohn’s disease (CD) leads to a poor health-related quality of life (HRQoL). This review aimed to investigate the effect of biological agents and small-molecule drugs in improving the HRQoL of patients with moderate to severe CD. We adopted a systematic protocol to search PubMed and Cochrane Central Register of Controlled Trials (CENTRAL), which was supplemented with manual searches. Eligible studies were RCTs that matched the research objective based on population, intervention, comparison and outcomes. Studies in paediatric populations, reviews and conference abstracts were excluded. Covidence was used for screening and data extraction. We assessed all research findings using RoB2 and reported them narratively. We included 16 multicentre, multinational RCTs in this review. Of the 15 studies that compared the effect of an intervention to a placebo, 9 were induction studies and 6 investigated maintenance therapy. Of these, 13 studies showed a significant (p < 0.05) improvement in the HRQoL of patients with CD. One non-inferiority study compared the intervention with another active drug and favoured the intervention. This systematic review reported a substantial improvement in the HRQoL of patients with CD using biological agents and small-molecule drugs. These pharmaceutical substances have the potential to improve the HRQoL of patients with CD. However, further large clinical trials with long-term follow-up are essential to validate these findings.
format Online
Article
Text
id pubmed-9267515
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92675152022-07-09 Health-Related Quality of Life of Patients Treated with Biological Agents and New Small-Molecule Drugs for Moderate to Severe Crohn’s Disease: A Systematic Review Aladraj, Hasan Abdulla, Mohamed Guraya, Salman Yousuf Guraya, Shaista Salman J Clin Med Systematic Review Crohn’s disease (CD) leads to a poor health-related quality of life (HRQoL). This review aimed to investigate the effect of biological agents and small-molecule drugs in improving the HRQoL of patients with moderate to severe CD. We adopted a systematic protocol to search PubMed and Cochrane Central Register of Controlled Trials (CENTRAL), which was supplemented with manual searches. Eligible studies were RCTs that matched the research objective based on population, intervention, comparison and outcomes. Studies in paediatric populations, reviews and conference abstracts were excluded. Covidence was used for screening and data extraction. We assessed all research findings using RoB2 and reported them narratively. We included 16 multicentre, multinational RCTs in this review. Of the 15 studies that compared the effect of an intervention to a placebo, 9 were induction studies and 6 investigated maintenance therapy. Of these, 13 studies showed a significant (p < 0.05) improvement in the HRQoL of patients with CD. One non-inferiority study compared the intervention with another active drug and favoured the intervention. This systematic review reported a substantial improvement in the HRQoL of patients with CD using biological agents and small-molecule drugs. These pharmaceutical substances have the potential to improve the HRQoL of patients with CD. However, further large clinical trials with long-term follow-up are essential to validate these findings. MDPI 2022-06-28 /pmc/articles/PMC9267515/ /pubmed/35807044 http://dx.doi.org/10.3390/jcm11133743 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Aladraj, Hasan
Abdulla, Mohamed
Guraya, Salman Yousuf
Guraya, Shaista Salman
Health-Related Quality of Life of Patients Treated with Biological Agents and New Small-Molecule Drugs for Moderate to Severe Crohn’s Disease: A Systematic Review
title Health-Related Quality of Life of Patients Treated with Biological Agents and New Small-Molecule Drugs for Moderate to Severe Crohn’s Disease: A Systematic Review
title_full Health-Related Quality of Life of Patients Treated with Biological Agents and New Small-Molecule Drugs for Moderate to Severe Crohn’s Disease: A Systematic Review
title_fullStr Health-Related Quality of Life of Patients Treated with Biological Agents and New Small-Molecule Drugs for Moderate to Severe Crohn’s Disease: A Systematic Review
title_full_unstemmed Health-Related Quality of Life of Patients Treated with Biological Agents and New Small-Molecule Drugs for Moderate to Severe Crohn’s Disease: A Systematic Review
title_short Health-Related Quality of Life of Patients Treated with Biological Agents and New Small-Molecule Drugs for Moderate to Severe Crohn’s Disease: A Systematic Review
title_sort health-related quality of life of patients treated with biological agents and new small-molecule drugs for moderate to severe crohn’s disease: a systematic review
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9267515/
https://www.ncbi.nlm.nih.gov/pubmed/35807044
http://dx.doi.org/10.3390/jcm11133743
work_keys_str_mv AT aladrajhasan healthrelatedqualityoflifeofpatientstreatedwithbiologicalagentsandnewsmallmoleculedrugsformoderatetoseverecrohnsdiseaseasystematicreview
AT abdullamohamed healthrelatedqualityoflifeofpatientstreatedwithbiologicalagentsandnewsmallmoleculedrugsformoderatetoseverecrohnsdiseaseasystematicreview
AT gurayasalmanyousuf healthrelatedqualityoflifeofpatientstreatedwithbiologicalagentsandnewsmallmoleculedrugsformoderatetoseverecrohnsdiseaseasystematicreview
AT gurayashaistasalman healthrelatedqualityoflifeofpatientstreatedwithbiologicalagentsandnewsmallmoleculedrugsformoderatetoseverecrohnsdiseaseasystematicreview